INS and cancer: Using the hyperinsulinemic-euglycemic clamp, the gold standard for measuring insulin sensitivity, whole-body insulin resistance has been established in pancreatic [5], lung [6,7,8], gastrointestinal system [7,8,9], and colorectal [8,10] cancers; although none of those studies determined tissue-specific glucose uptake.